JW Pharmaceutical Corporation (001065.KS)
KRW 29450.0
(-1.01%)
KRW 29450.0
(-1.01%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 748.52 Billion KRW | 9.38% |
| 2022 | 684.35 Billion KRW | 12.82% |
| 2021 | 606.58 Billion KRW | 10.83% |
| 2020 | 547.33 Billion KRW | 7.04% |
| 2019 | 511.33 Billion KRW | -4.81% |
| 2018 | 537.18 Billion KRW | 6.81% |
| 2017 | 502.91 Billion KRW | 7.58% |
| 2016 | 467.46 Billion KRW | 7.62% |
| 2015 | 434.35 Billion KRW | 5.22% |
| 2014 | 412.79 Billion KRW | 4.72% |
| 2013 | 394.18 Billion KRW | -0.73% |
| 2012 | 397.08 Billion KRW | -7.87% |
| 2011 | 431 Billion KRW | -2.77% |
| 2010 | 443.27 Billion KRW | -2.61% |
| 2009 | 455.14 Billion KRW | 4.0% |
| 2008 | 437.64 Billion KRW | 13.67% |
| 2007 | 385.01 Billion KRW | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 180.59 Billion KRW | -11.91% |
| 2024 Q2 | 172.27 Billion KRW | -4.61% |
| 2023 Q3 | 184.2 Billion KRW | -0.92% |
| 2023 Q2 | 185.92 Billion KRW | 7.23% |
| 2023 Q1 | 173.38 Billion KRW | -10.24% |
| 2023 FY | 748.52 Billion KRW | 9.38% |
| 2023 Q4 | 205.01 Billion KRW | 11.3% |
| 2022 Q4 | 193.15 Billion KRW | 13.73% |
| 2022 FY | 684.35 Billion KRW | 12.82% |
| 2022 Q1 | 156.34 Billion KRW | -7.75% |
| 2022 Q2 | 165 Billion KRW | 5.54% |
| 2022 Q3 | 169.84 Billion KRW | 2.93% |
| 2021 Q1 | 142.09 Billion KRW | -1.81% |
| 2021 Q2 | 146.02 Billion KRW | 2.77% |
| 2021 Q3 | 148.99 Billion KRW | 2.03% |
| 2021 FY | 606.58 Billion KRW | 10.83% |
| 2021 Q4 | 169.46 Billion KRW | 13.74% |
| 2020 Q4 | 144.71 Billion KRW | 5.52% |
| 2020 Q1 | 129.02 Billion KRW | 13.27% |
| 2020 FY | 547.33 Billion KRW | 7.04% |
| 2020 Q3 | 137.14 Billion KRW | 0.5% |
| 2020 Q2 | 136.45 Billion KRW | 5.76% |
| 2019 Q1 | 130.27 Billion KRW | 2.31% |
| 2019 FY | 511.33 Billion KRW | -4.81% |
| 2019 Q2 | 134.13 Billion KRW | 2.96% |
| 2019 Q4 | 113.9 Billion KRW | -14.37% |
| 2019 Q3 | 133.01 Billion KRW | -0.84% |
| 2018 Q4 | 127.33 Billion KRW | -13.09% |
| 2018 Q3 | 146.51 Billion KRW | 10.43% |
| 2018 Q2 | 132.67 Billion KRW | 1.55% |
| 2018 Q1 | 130.65 Billion KRW | 4.46% |
| 2018 FY | 537.18 Billion KRW | 6.81% |
| 2017 Q4 | 125.07 Billion KRW | -6.15% |
| 2017 Q3 | 133.26 Billion KRW | 9.87% |
| 2017 Q2 | 121.29 Billion KRW | -1.62% |
| 2017 Q1 | 123.28 Billion KRW | 9.29% |
| 2017 FY | 502.91 Billion KRW | 7.58% |
| 2016 Q3 | 118.89 Billion KRW | 2.04% |
| 2016 Q2 | 116.51 Billion KRW | -2.28% |
| 2016 Q1 | 119.23 Billion KRW | 12.63% |
| 2016 FY | 467.46 Billion KRW | 7.62% |
| 2016 Q4 | 112.81 Billion KRW | -5.12% |
| 2015 Q1 | 106.17 Billion KRW | -11.01% |
| 2015 Q4 | 105.86 Billion KRW | -4.21% |
| 2015 Q3 | 110.52 Billion KRW | -1.13% |
| 2015 Q2 | 111.78 Billion KRW | 5.29% |
| 2015 FY | 434.35 Billion KRW | 5.22% |
| 2014 FY | 412.79 Billion KRW | 4.72% |
| 2014 Q4 | 119.3 Billion KRW | 16.35% |
| 2014 Q3 | 102.53 Billion KRW | 4.64% |
| 2014 Q2 | 97.99 Billion KRW | 5.43% |
| 2014 Q1 | 92.95 Billion KRW | 0.4% |
| 2013 Q4 | 92.57 Billion KRW | -9.72% |
| 2013 FY | 394.18 Billion KRW | -0.73% |
| 2013 Q1 | 91.59 Billion KRW | -8.74% |
| 2013 Q2 | 107.46 Billion KRW | 17.32% |
| 2013 Q3 | 102.54 Billion KRW | -4.58% |
| 2012 Q4 | 100.36 Billion KRW | 2.24% |
| 2012 FY | 397.08 Billion KRW | -7.87% |
| 2012 Q3 | 98.16 Billion KRW | 1.83% |
| 2012 Q1 | 102.15 Billion KRW | 0.0% |
| 2012 Q2 | 96.39 Billion KRW | -5.64% |
| 2011 Q4 | - KRW | -100.0% |
| 2011 Q2 | 108.17 Billion KRW | 0.14% |
| 2011 Q1 | 108.02 Billion KRW | -3.39% |
| 2011 Q3 | 107.32 Billion KRW | -0.78% |
| 2011 FY | 431 Billion KRW | -2.77% |
| 2010 Q4 | 111.81 Billion KRW | 5.36% |
| 2010 FY | 443.27 Billion KRW | -2.61% |
| 2010 Q1 | 112.62 Billion KRW | -0.38% |
| 2010 Q3 | 106.12 Billion KRW | -5.85% |
| 2010 Q2 | 112.71 Billion KRW | 0.08% |
| 2009 Q2 | 118.45 Billion KRW | 11.2% |
| 2009 Q4 | 113.04 Billion KRW | -3.48% |
| 2009 Q3 | 117.12 Billion KRW | -1.13% |
| 2009 Q1 | 106.52 Billion KRW | -1.32% |
| 2009 FY | 455.14 Billion KRW | 4.0% |
| 2008 Q2 | 112.46 Billion KRW | 5.69% |
| 2008 Q3 | 110.82 Billion KRW | -1.46% |
| 2008 FY | 437.64 Billion KRW | 13.67% |
| 2008 Q4 | 107.94 Billion KRW | -2.6% |
| 2008 Q1 | 106.41 Billion KRW | 13.33% |
| 2007 Q4 | 93.89 Billion KRW | -4.79% |
| 2007 Q1 | 90.51 Billion KRW | 0.0% |
| 2007 Q2 | 101.97 Billion KRW | 12.66% |
| 2007 FY | 385.01 Billion KRW | 0.0% |
| 2007 Q3 | 98.62 Billion KRW | -3.29% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 137.2 Billion KRW | -445.535% |
| Dong-A Socio Holdings Co., Ltd. | 1132 Billion KRW | 33.876% |
| Ildong Holdings Co., Ltd. | 638.44 Billion KRW | -17.242% |
| HANDOK Inc. | 522.74 Billion KRW | -43.193% |
| Kukje Pharma Co., Ltd. | 135.37 Billion KRW | -452.938% |
| Yuhan Corporation | 1858.98 Billion KRW | 59.735% |
| Dong-A ST Co., Ltd. | 663.98 Billion KRW | -12.733% |
| SAMSUNG PHARM. Co., LTD. | 51.95 Billion KRW | -1340.72% |
| Hanmi Pharm. Co., Ltd. | 1490.88 Billion KRW | 49.793% |
| Hanall Biopharma Co.,Ltd | 134.9 Billion KRW | -454.835% |
| Ilyang Pharmaceutical Co.,Ltd | 370.53 Billion KRW | -102.011% |
| Dong Sung Bio Pharm.Co.,Ltd. | 88.59 Billion KRW | -744.899% |
| MYUNGMOON Pharm co.,Ltd | 169.56 Billion KRW | -341.433% |
| Hana Pharm Co., Ltd. | 224.45 Billion KRW | -233.484% |
| Yuyu Pharma, Inc. | 137.2 Billion KRW | -445.535% |
| Ilsung Pharmaceuticals Co., Ltd. | 78.05 Billion KRW | -858.995% |
| REYON Pharmaceutical Co., Ltd. | 151.07 Billion KRW | -395.48% |
| Aprogen pharmaceuticals,Inc. | 87.36 Billion KRW | -756.794% |
| JW Holdings Corporation | 928.07 Billion KRW | 19.346% |
| Ildong Pharmaceutical Co., Ltd. | 600.75 Billion KRW | -24.597% |
| Chong Kun Dang Pharmaceutical Corp. | 1669.4 Billion KRW | 55.162% |
| Shin Poong Pharm.Co.,Ltd. | 200.22 Billion KRW | -273.836% |
| Hyundai Pharmaceutical Co., Ltd. | 180.76 Billion KRW | -314.094% |
| Samil Pharmaceutical Co.,Ltd | 196.34 Billion KRW | -281.229% |
| Jeil Pharmaceutical Co.,Ltd | 726.39 Billion KRW | -3.047% |
| Yuyu Pharma, Inc. | 137.2 Billion KRW | -445.535% |
| Kwang Dong Pharmaceutical Co., Ltd. | 1514.45 Billion KRW | 50.574% |
| Daewoong pharmaceutical Co.,Ltd | 1375.32 Billion KRW | 45.575% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | 0.0% |
| Yuhan Corporation | 1858.98 Billion KRW | 59.735% |
| Jeil Pharma Holdings Inc | 794.71 Billion KRW | 5.812% |
| Yungjin Pharm. Co., Ltd. | 234.9 Billion KRW | -218.654% |
| Suheung Co., Ltd. | 594.56 Billion KRW | -25.894% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | 0.0% |
| Samjin Pharmaceuticals Co., Ltd. | 292.12 Billion KRW | -156.232% |
| Korea United Pharm Inc. | 278.94 Billion KRW | -168.344% |
| CKD Bio Corp. | 160.35 Billion KRW | -366.8% |
| Daewon Pharmaceutical Co., Ltd. | 526.95 Billion KRW | -42.048% |
| Dongwha Pharm.Co.,Ltd | 361.1 Billion KRW | -107.286% |
| Whan In Pharm Co.,Ltd. | 230.39 Billion KRW | -224.89% |
| Shin Poong Pharm.Co.,Ltd. | 200.22 Billion KRW | -273.836% |
| Chong Kun Dang Holdings Corp. | 879.78 Billion KRW | 14.919% |
| Boryung Corporation | 859.62 Billion KRW | 12.924% |
| Bukwang Pharmaceutical Co., Ltd. | 125.92 Billion KRW | -494.407% |
| Ilyang Pharmaceutical Co.,Ltd | 370.53 Billion KRW | -102.011% |
| JW Lifescience Corporation | 206.86 Billion KRW | -261.851% |